Ontak denileukin diftitox: Phase III started

Eisai disclosed in its fiscal 1Q11 earnings ending June 30 that it began a U.S. Phase III trial to evaluate Ontak. The product is marketed in the U.S. to treat cutaneous T cell lymphoma (CTCL) in pati...